Zobrazeno 1 - 10
of 77
pro vyhledávání: '"W. Schmid-Burgk"'
Publikováno v:
Acta Psychiatrica Scandinavica. 92:260-265
The efficacy and the safety of moclobemide (400-600 mg/day), a reversible and selective inhibitor of monoamine oxidase-A (RIMA) and of clomipramine (100-150 mg/day) were compared respectively in 98 and 93 nonmelancholic, nonpsychotic out-patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b31ca74ed910e0c1f0b1e94f6d0918ff
https://doi.org/10.1111/j.1600-0447.1995.tb09580.x
https://doi.org/10.1111/j.1600-0447.1995.tb09580.x
Publikováno v:
Clinical Neuropharmacology. 17:S74-S87
Safety aspects [adverse events, blood pressure and heart rate, weight, and laboratory tests (liver parameters, hemoglobin, leukocytes)] of long-term treatment in 1,120 patients are discussed. Adverse events during this long-term treatment were also c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b768a575445ca503396143d11389c20
https://doi.org/10.1097/00002826-199417001-00009
https://doi.org/10.1097/00002826-199417001-00009
Publikováno v:
Neuro-Ophthalmology. 13:5-12
On separate test days, seven healthy test subjects were given a single oral dose each of moclobemide (150 mg), desipramine (50 mg), amitriptyline (50 mg) or placebo in randomized order and under double-blind conditions. Horizontal 30° saccades were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7218625871d409a3358736af8ce71e11
https://doi.org/10.3109/01658109309036996
https://doi.org/10.3109/01658109309036996
Publikováno v:
International Clinical Psychopharmacology. 7:123-132
Moclobemide, a specific reversible inhibitor of monoamine oxidase that shows a preference for the A isoenzyme, has been developed as a new antidepressive agent. Unlike earlier generation monoamine oxidase inhibitors, moclobemide is devoid of any clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be1f2f16ea847e0e7ffc3c8b4ff1a842
https://doi.org/10.1097/00004850-199300730-00001
https://doi.org/10.1097/00004850-199300730-00001
Publikováno v:
Psychopharmacology. 106:S24-S31
Interactions may occur on pharmacological or pharmacokinetic grounds. Both types of interactions are discussed in relationship with the pharmacological and pharmacokinetic data of moclobemide, a reversible MAO-inhibitor. A variety of interaction stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b92d1d990913577f3bc7e5cde1e64e02
https://doi.org/10.1007/bf02246229
https://doi.org/10.1007/bf02246229
Publikováno v:
Acta psychiatrica Scandinavica. 92(4)
The efficacy and the safety of moclobemide (400-600 mg/day), a reversible and selective inhibitor of monoamine oxidase-A (RIMA) and of clomipramine (100-150 mg/day) were compared respectively in 98 and 93 nonmelancholic, nonpsychotic out-patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5caa46f7914d7ac489f2f8f32f37c75f
https://pubmed.ncbi.nlm.nih.gov/8848950
https://pubmed.ncbi.nlm.nih.gov/8848950
Publikováno v:
Acta psychiatrica Scandinavica. Supplementum. 386
Noradrenaline (NA) and serotonin, monoamines that increase neurotransmission at the monoaminergic synapses, remain primary targets for antidepressant drugs. To help elucidate NA's role in the action of antidepressants, a model was set up allowing for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cdfd3f5d9c7310bace22f33b9bac9e4
https://pubmed.ncbi.nlm.nih.gov/7717090
https://pubmed.ncbi.nlm.nih.gov/7717090
Publikováno v:
Canadian journal of psychiatry. Revue canadienne de psychiatrie. 37
Moclobemide--a new, safer antidepressant drug--is described and clinical studies are reviewed. Moclobemide represents a new class of drug, the so-called RIMA compounds--reversible inhibitors of MAO-A. Unlike classical monoamine oxidase (MAO) inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::42b1f68c0bbf048e3770883812917d38
https://pubmed.ncbi.nlm.nih.gov/1394030
https://pubmed.ncbi.nlm.nih.gov/1394030
Publikováno v:
Acta Psychiatrica Scandinavica. 82:57-58
Moclobemide was compared with imipramine and placebo in the treatment of major depressive episodes in 75 outpatients. The dosage of moclobemide (25 patients) was 300 mg daily for the first 5 days, after which it could be increased to 600 mg. Imiprami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a63a06dd6ac8abadf5ef6ec3d15e084f
https://doi.org/10.1111/j.1600-0447.1990.tb05331.x
https://doi.org/10.1111/j.1600-0447.1990.tb05331.x
Autor:
M. Versiani, U. Oggero, P. Alterwain, R. Capponi, F. Dajas, G. Heinze-Martin, C.A. Marquez, M.A. Poleo, L.E. Rivero-Almanzor, L. Rossel, W. Schmid-Burgk, R. Ucha-Udabe
Publikováno v:
British Journal of Psychiatry. 155:72-77
Patients (n = 490) suffering from a major depressive episode according to DSM-III criteria were randomly allocated to groups receiving either moclobemide, imipramine, or placebo treatment. Subjects were treated as out-patients for 6 weeks. On overall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccb97c2d069e86ee7929dc3f09ff84b4
https://doi.org/10.1192/s0007125000297523
https://doi.org/10.1192/s0007125000297523